MRUS250117P45000
- 5.90
- +0.30+5.36%
Merus Newsroom
Merus N.V. (MRUS): The Biotech Stock With Biggest Upside Potential
What's Going On With Merus Stock Monday?
Merus Shares Are Trading Lower. The Company Announced a Research Collaboration and License Agreement With Biohaven to Co-develop Three Novel Bispecific Antibody Drug Conjugates.
Express News | Biohaven Ltd - Merus Will Receive an Upfront Payment and License Fee at ADC Candidate Nomination of First Program
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
We Think Merus (NASDAQ:MRUS) Can Afford To Drive Business Growth
CCORF Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $67
Canaccord Genuity Sticks to Its Buy Rating for Merus (MRUS)
Merus Announces First Patient Dosed In The Phase 2 Trial Evaluating Petosemtamab Monotherapy In Heavily Pretreated Metastatic Colorectal Cancer
BofA Securities Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $73
BofA Securities Maintains Merus(MRUS.US) With Buy Rating, Announces Target Price $73
Promising Potential of Merus's Petosemtamab in HNSCC: A Buy Recommendation
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy
A Quick Look at Today's Ratings for Merus(MRUS.US), With a Forecast Between $67 to $97
Merus Positioned for Growth Amid Promising Clinical Data and Resilience to Market Fluctuations
Merus Price Target Raised to $97.00/Share From $89.00 by Citigroup
Merus Is Maintained at Buy by Citigroup
Analysts Offer Insights on Healthcare Companies: Geron (GERN), Merus (MRUS) and C4 Therapeutics (CCCC)
Truist Financial Maintains Merus(MRUS.US) With Buy Rating